

REMARKS

Claims 5-8 and 13-15 are pending, in this application. Claims 13-15 has been withdrawn from consideration and claims 5-8 stand rejected. Claims 1-4, 9-12 and 16-20 were cancelled without prejudice or disclaimer by way of Preliminary Amendment filed with the subject application on December 8, 1998. By virtue of this amendment claim 5 is cancelled without prejudice or disclaimer, claims 6, 7 and 8 are amended and new claims 21 to 26 are added.

Support for the amendments and new claims may be found throughout the specification. For example, support for the amendments to claims 6, 7 and 8 and new claims 21-26 may be found at page 4, lines 16 -18 and lines 25-27 and in the claims as originally filed. Thus no new matter has been added by this amendment.

With respect to all amendments and cancelled claims, Applicants have not dedicated or abandoned any unclaimed subject matter and moreover have not acquiesced to any rejections and/or objections made by the Patent and Trademark Office. Applicants reserve the right to pursue prosecution of any presently excluded claim embodiments in future continuation and/or divisional applications.

Submission of Formal Drawings

The Notice of Draftsperson's Patent Drawing accompanying the Office action (paper 32) objected to informalities in Figures 1-4 as originally filed and requested submission of corrected drawings for Figures 1-4. Filed concurrently herewith is one set (ten sheets, four figures) of formal drawings for Figures 1-4 in the above-identified patent application. Kindly substitute the enclosed formal drawings for the drawings submitted with the originally filed application.

Sequence Compliance

The Office alleges that the Sequence Listing filed June 9, 2003 does not comply with Sequence Listing Rules as set forth in 37 C.F.R §1.821-§1.825. In compliance with 37 C.F.R §1.821-§1.825, attached hereto is a substitute paper copy of the Sequence Listing, a substitute disk containing a computer readable copy of the Sequence Listing, and a Statement Under 37 C.F.R §1.821-§1.825§1.821(f) stating that the content of the paper copy of the Sequence Listing and computer readable form are the same.

In the Sequence Listing filed herewith SEQ ID NO: 3 corresponds to the amino acid sequence which begins at nucleotides 51-53 (ATG= Met) and ends at nucleotides 1158-1160 of SEQ ID No.: 1 (TAG=Stop) and SEQ ID NO: 6 corresponds to the amino acid sequence which begins at nucleotides 58-60 (ATG= Met) and ends at nucleotides 1180-1182 of SEQ ID No.: 4 (TAG=Stop). Support for these sequences may be found throughout the specification as for example at page 4, lines 16 -18 and Figure 1 for SEQ ID NO.: 3 and page 4, lines 25-27 and Figure 3 for SEQ ID NO.: 6. SEQ ID NOS.: 24 and 25 represent the entire amino acid sequences shown in Figures 1 and 3 respectively. Thus no new matter has been added. Entry of the attached Sequence Listing into the specification is respectfully requested.

Rejections under 35 U.S.C. § 112, Second Paragraph

Claims 5-8 are rejected under 35 U.S.C. §112, second as being indefinite for allegedly failing to particularly point out and distinctly claim the subject matter which Applicant regards as their invention. With respect to claim 5, this rejection has been rendered moot by cancellation of said claim without prejudice or disclaimer. With respect to the claim 8, in the interest of facilitating prosecution only, Applicants have amended claim 8 to recite the sequence identifiers for SEQ ID NOS.: 3 and 6. Accordingly, Applicants respectfully request withdrawal of this ground of rejection.

Claims 6 and 7 are also rejected as allegedly being indefinite. Applicants have amended claims 6 and 7 to recite SEQ ID NO. 3 and SEQ ID NO.: 6 which are set forth in the Sequence

Listing filed concurrently herewith. Accordingly, Applicants respectfully requests withdrawal of this ground of rejection.

Rejections under 35 U.S.C. § 112, First Paragraph

Claims 5 and 8 are rejected under 35 U.S.C. §112 first paragraph as allegedly containing subject matter which was not enabled by the specification and containing subject matter which was not described in the specification. Cancellation of claim 5 without prejudice or disclaimer renders the Examiner's rejection with respect to that claim moot. With respect to the claim 8, in the interest of facilitating prosecution only, Applicants have amended claim 8 to recite the sequence identifiers for the mouse and human PAR 3 amino acid sequences exemplified in the instant application. Accordingly, Applicants request withdrawal of this ground of rejection.

Rejections under 35 U.S.C. § 102

Claims 5 and 8 are rejected under 35 U.S.C. §102(e) as allegedly being anticipated by Coleman et al. (US 5,686,597). With respect to claim 5, this rejection has been rendered moot by cancellation of said claim without prejudice or disclaimer. With respect to the claim 8, in the interest of facilitating prosecution, Applicants have amended claim 8 to recite the sequence identifiers for SEQ ID NOS.: 3 and 6. Accordingly, withdrawal of this ground of rejection is respectfully requested.

Claims 1-2 and 9-10 are rejected under 35 U.S.C. §102(b) as allegedly being anticipated by Nystedt et al. (PNAS, 1994). Claims 1-2 and 9-10 were cancelled without prejudice or disclaimer in a preliminary Amendment filed concurrently with the instant application on December 8, 1998. Applicant respectfully submits that the Examiner's rejection with respect to those claims is moot. Accordingly withdrawal of this ground of rejection is requested.


CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 220002060310. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 10, 2004

Respectfully submitted,

By 

Carol M. Gruppi

Registration No.: 37,341

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304

(650) 813-5777